Buy this Article for $3.95

Have a coupon or promotional code? Enter it here:

When you buy this you'll get access to the ePub version, a downloadable PDF, and the ability to print the full article.

Authors

  1. Geiger, Haden PharmD
  2. Samai, Kathryn PharmD, BCPS

Abstract

Objective: To provide a concise review of the literature on desmopressin use for antiplatelet reversal in patients with intracranial hemorrhage.

 

Data Sources: Source data were obtained from a PubMed literature review.

 

Study Selection: Studies addressing desmopressin for antiplatelet reversal.

 

Data Extraction: Relevant studies were reviewed and included through consensus of the authors. The following aspects of each study were identified, abstracted, and analyzed: study population, study design, methods, results, and relevant implications for practice.

 

Data Synthesis: A growing body of evidence continues to provide mixed results for the use of desmopressin in patients presenting with antiplatelet-associated intracranial hemorrhage. The potential benefit outweighs the possible risks associated with a one-time dose. In addition to desmopressin, platelets should only be considered in patients undergoing a neurosurgical procedure until further and superior evidence is available. Guidelines recommend a weight-based approach for desmopressin dosing at 0.4 mcg/kg over 30 min.

 

Conclusions: The available evidence supports desmopressin as potentially beneficial with minimal risk for use in patients with antiplatelet-associated intracranial hemorrhage.